本帖最后由 choi 于 1-31-2016 18:17 编辑
(3) Medicine | Curing Multiple Sclerosis; Stem cells are starting to prove their value as medical treatments.
http://www.economist.com/news/sc ... nts-curing-multiple
Quote:
"a relapse rate of around 10% within five years
"such drugs [that treat multiple sclerosis] can slow the progression of the disease, they cannot do what the stem-cell therapy seems able to, which is to reverse it and improve patients’ quality of life—for example by allowing them to walk again.
"Dr Burt reckons, a stem-cell transplant in America costs, all in, $120,000—and that sum would be lower in countries with less-expensive health-care systems. Indeed, doctors in Britain think the treatment should cost hospitals about £30,000 (just over $40,000).
Note:
(a) "THIRTY years ago a young haematologist called Richard Burt was training at Johns Hopkins University, in Baltimore."
(i) That was when Richard K Burt, MD, was a fellow, having completed his residency.
(ii) Dr Richard Burt. Stem Cell Research Facts, undated.
www.stemcellresearchfacts.org/dr-richard-burt/
It sounds too rosy.
(iii) What nags me is three decades latter, Dr Burt can only publish the result of an uncontrolled study, which is meaningless in science -- particularly in light of highly unpredictable course of these diseases (with or without treatment). See
Burt RK et al, Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation with Neurological Disability in Patients with Relapsing-Remitting Multiple Sclerosis. JAMA, 313: 275-284 (Jan 20, 2015)
www.ncbi.nlm.nih.gov/pubmed/25602998
("These preliminary findings from this uncontrolled study require confirmation in randomized trials")
(b) "And other conditions, too, seem susceptible to the stem-cell approach. Mesoblast, an Australian company, received approval last September for a stem-cell treatment for graft-versus-host disease, in which the transplanted tissue attacks the host."
Press release: Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan. Mesoblast, Sept 3, 2015
https://globenewswire.com/news-r ... oduct-In-Japan.html
(Japan recommended for approval JR-031, developed by Mesoblast's Japanese partner JCR Pharmaceuticals Co, Ltd JCRファーマ株式会社) |